Roche began commercial shipping of Axelios 1, a new next-generation sequencing platform designed to compete with Illumina in accuracy, speed, flexibility, scalability, and cost. The launch signals Roche’s push to capture sequencing share in clinical and research workflows following a prolonged rollout.